Translational Oncology

2.4k papers and 42.0k indexed citations i.

About

The 2.4k papers published in Translational Oncology in the last decades have received a total of 42.0k indexed citations. Papers published in Translational Oncology usually cover Molecular Biology (1.1k papers), Oncology (986 papers) and Cancer Research (713 papers) specifically the topics of Cancer-related molecular mechanisms research (203 papers), Cancer Immunotherapy and Biomarkers (202 papers) and RNA modifications and cancer (195 papers). The most active scholars publishing in Translational Oncology are Pengfei Xu, Yue Xi, Doménico Ribatti, Roberto Tamma, Tiziana Annese, Xiaosheng Wang, Zhixian Liu, Xiaoqi Liu, Yi Sun and Zhen Wang.

In The Last Decade

Fields of papers published in Translational Oncology

Since Specialization
EngineeringComputer SciencePhysics and AstronomyMathematicsEarth and Planetary SciencesEnergyEnvironmental ScienceMaterials ScienceChemical EngineeringChemistryAgricultural and Biological SciencesVeterinaryDecision SciencesArts and HumanitiesBusiness, Management and AccountingSocial SciencesPsychologyEconomics, Econometrics and FinanceHealth ProfessionsDentistryMedicineBiochemistry, Genetics and Molecular BiologyNeuroscienceNursingImmunology and MicrobiologyPharmacology, Toxicology and Pharmaceutics

This network shows the specialization of papers published in Translational Oncology. Nodes represent fields, and links connect fields that are likely to share authors.

Countries where authors publish in Translational Oncology

Since Specialization
Total citations of papers

This map shows the geographic distribution of research published in Translational Oncology. It shows the number of citations received by papers published by authors working in each country. You can also color the map by specialization and compare the number of papers published in Translational Oncology with the expected number of papers based on a country's size and research output (numbers larger than one mean the country's share of papers is larger than expected).

Rankless by CCL
2025